title: The antileukemic potential of natural killer cells.
abstract: The antileukemic potential of natural killer (NK) cells has over the years raised considerable interest and new immune-based treatment protocols characterized by the infusion of freshly isolated or ex vivo activated and expanded effectors have been designed. Several aspects still need to be addressed, including the optimal timing of NK infusion during the course of the disease, the best preparative regimen, the origin of NK cells and the possible need of ex vivo NK cell manipulation before the infusion. The aims of this review are to discuss the experimental and clinical data available on the role played by NK cells for leukemia patients and to revise the different good manufacturing practice protocols for ex vivo manipulation of these effector cells.
authors.affiliation: Hematology, Department of Cellular Biotechnologies & Hematology, Sapienza University, Rome, Italy.
authors.forename: Giovanni F
authors.initials: GF
authors.lastname: Torelli
authors.affiliation: Hematology, Department of Cellular Biotechnologies & Hematology, Sapienza University, Rome, Italy.
authors.forename: Nadia
authors.initials: N
authors.lastname: Peragine
authors.affiliation: Hematology, Department of Cellular Biotechnologies & Hematology, Sapienza University, Rome, Italy.
authors.forename: Paola
authors.initials: P
authors.lastname: Mariglia
authors.affiliation: Hematology, Department of Cellular Biotechnologies & Hematology, Sapienza University, Rome, Italy.
authors.forename: Robin
authors.initials: R
authors.lastname: Foà
mesh_terms: D000818:Animals; D002985:Clinical Protocols; D002986:Clinical Trials as Topic; D003602:Cytotoxicity, Immunologic; D006801:Humans; D016219:Immunotherapy, Adoptive; D007694:Killer Cells, Natural / Q000276:immunology* / Q000637:transplantation; D007938:Leukemia / Q000276:immunology / Q000628:therapy*
keywords: good manufacturing practice; leukemia; natural killer cells